Efficacy and Safety Profile of Risperidone Long-acting Injection in Adolescents in a Real-life Setting
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Objective: Risperidone long-acting injection (RLAI) was shown to be an alternative option in adult patients, but there is not available data in child and adolescents about this medication. The aim of this study is to evaluate the safety and efficiency profile of RLAI in a group of adolescents. Methods: Eleven cases with conduct disorder and severe aggressive behaviors were initiated treatment with risperidone oral form. All cases were then shifted to RLAI 25 mg injection in each 15 days due to poor compliance to oral risperidone treatment. Efficiency of treatment included indicators of clinical severity and improvement, which were evaluated by Clinical Global Impression-Severity (CGI-S) and Improvement (CGI-I). Safety evaluation was performed by using Extrapyramidal Symptoms Rating Scale, and by monitoring body weight. Follow-up visits were done at the treatment initiation, and 8th, 16th, and 24th weeks of first injection. Results: Study included 9 girls, and 2 boys, with a mean age of 14.9±1.0 years. The CGI-S scores decreased from 6.6±0.5 at the beginning to 2.2±1.1 at the last visit (p＜0.001), which is a very significant decrease through better clinical level. The CGI-I scores were also improved significantly from 2.4±0.5 to 1.9±0.5 at 24th week (p=0.001). Safety parameters were also showed favorable results, which there was no significant weight gain (p=0.076), and well-tolerated extrapyramidal adverse effects. Conclusion: Our results showed that RLAI is an efficient and safe medication option in the treatment of psychiatric disorders and severe behavioral problems in adolescents with low-compliance to oral treatment in our cases
Abstract
Objective: Risperidone long-acting injection (RLAI) was shown to be an alternative option in adult patients, but there is not available data in child and adolescents about this medication. The aim of this study is to evaluate the safety and efficiency profile of RLAI in a group of adolescents. Methods: Eleven cases with conduct disorder and severe aggressive behaviors were initiated treatment with risperidone oral form. All cases were then shifted to RLAI 25 mg injection in each 15 days due to poor compliance to oral risperidone treatment. Efficiency of treatment included indicators of clinical severity and improvement, which were evaluated by Clinical Global Impression-Severity (CGI-S) and Improvement (CGI-I). Safety evaluation was performed by using Extrapyramidal Symptoms Rating Scale, and by monitoring body weight. Follow-up visits were done at the treatment initiation, and 8th, 16th, and 24th weeks of first injection. Results: Study included 9 girls, and 2 boys, with a mean age of 14.9±1.0 years. The CGI-S scores decreased from 6.6±0.5 at the beginning to 2.2±1.1 at the last visit (p＜0.001), which is a very significant decrease through better clinical level. The CGI-I scores were also improved significantly from 2.4±0.5 to 1.9±0.5 at 24th week (p=0.001). Safety parameters were also showed favorable results, which there was no significant weight gain (p=0.076), and well-tolerated extrapyramidal adverse effects. Conclusion: Our results showed that RLAI is an efficient and safe medication option in the treatment of psychiatric disorders and severe behavioral problems in adolescents with low-compliance to oral treatment in our cases
참고문헌 (26)
- Lewis M, "Violation of expectancy, loss of control, and anger expressions in young infants", Dev Psychol, 26, pp.745~751 (1990)[DOI]
- Alink LR, "The early childhood aggression curve: development of physical aggression in 10- to 50-month-old children", Child Dev, 77, pp.954~966 (2006)[DOI]
- Tremblay RE, "Physical aggression during early childhood: trajectories and predictors", Can Child Adolesc Psychiatr Rev, 14, pp.3~9 (2005)
- Raine A, "Biosocial studies of antisocial and violent behavior in children and adults: a review", J Abnorm Child Psychol, 30, pp.311~326 (2002)[DOI]
- American Psychiatric Association, "Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed." (2013), American Psychiatric Publishing
- Hamshere ML, "High loading of polygenic risk for ADHD in children with comorbid aggression", Am J Psychiatry, 170, pp.909~916 (2013)[DOI]
- Mandy W, "Three dimensions of oppositionality in autism spectrum disorder", J Abnorm Child Psychol, 42, pp.291~300 (2014)[DOI]
- Pope AW, "Predicting adolescent peer problems and antisocial activities: the relative roles of aggression and dysregulation", Dev Psychol, 35, pp.335~346 (1999)[DOI]
- White HR, "Moderators of the dynamic link between alcohol use and aggressive behavior among adolescent males", J Abnorm Child Psychol, 41, pp.211~222 (2013)[DOI]
- Schaeffer CM, "Modeling growth in boys' aggressive behavior across elementary school: links to later criminal involvement, conduct disorder, and antisocial personality disorder", Dev Psychol, 39, pp.1020~1035 (2003)[DOI]
- Volavka J, "Catecholamines and aggression: the role of COMT and MAO polymorphisms", Ann N Y Acad Sci, 1036, pp.393~398 (2004)
- Glennon J, "Paediatric European Risperidone Studies (PERS): context, rationale, objectives, strategy, and challenges", Eur Child Adolesc Psychiatry, 23, pp.1149~1160 (2014)[DOI]
- Ercan ES, "Risperidone in the treatment of conduct disorder in preschool children without intellectual disability", Child Adolesc Psychiatry Ment Health, 5, pp.10~ (2011)[DOI]
- Kane JM, "Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic", Am J Psychiatry, 160, pp.1125~1132 (2003)[DOI]
- Guy W, "ECDEU assessment manual for psychopharmacology", US Department of Health, Education, and Welfare; Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration; National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs, ~ (1976)
- Chouinard G, "Manual for the Extrapyramidal Symptom Rating Scale (ESRS)", Schizophr Res, 76, pp.247~265 (2005)[DOI]
- Tutkunkardas MD, "Long acting risperidone in an adolescent with conduct disorder: A case report", Psychopharmacol Bull, 44, pp.69~72 (2011)
- Peruzzolo TL, "Pharmacotherapy of bipolar disorder in children and adolescents: an update", Rev Bras Psiquiatr, 35, pp.393~405 (2013)[DOI]
- Ercan ES, "Risperidone in children and adolescents with conduct disorder: a single-center, open-label study", Curr Ther Res Clin Exp, 64, pp.55~64 (2003)[DOI]
- McCracken JT, "Risperidone in children with autism and serious behavioral problems", N Engl J Med, 347, pp.314~321 (2002)[DOI]
- Macfadden W, "Adjunctive long-acting risperidone in patients with bipolar disorder who relapse frequently and have active mood symptoms", BMC Psychiatry, 11, pp.171~ (2011)[DOI]
- Vieta E, "A long-term prospective study on the outcome of bipolar patients treated with long-acting injectable risperidone", World J Biol Psychiatry, 9, pp.219~224 (2008)[DOI]
- Macfadden W, "A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently", Bipolar Disord, 11, pp.827~839 (2009)[DOI]
- Quiroz JA, "Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder", Biol Psychiatry, 68, pp.156~162 (2010)[DOI]
- Boarati MA, "Six-month open-label follow-up of risperidone long-acting injection use in pediatric bipolar disorder", Prim Care Companion CNS Disord, 15 (2013)
- Jerrell JM, "Childhood treatment with psychotropic medication and development of comorbid medical conditions in adolescent-onset bipolar disorder", Hum Psychopharmacol, 26, pp.451~459 (2011)[DOI]